Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.54 |
| ▸ | PRKCI | P41743 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 17/20 | 0.52 |
| ▸ | JAK3 | P52333 | 16/20 | 0.52 |
| ▸ | JAK1 | P23458 | 13/20 | 0.52 |
| ▸ | TYK2 | P29597 | 5/20 | 0.51 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29713778 | 1.00 | AXL (0.54) | AXLPRKCIJAK2JAK3JAK1 | |
| SCHEMBL1154022 | 0.85 | AXL (0.56) | AXLPRKCIJAK2JAK3JAK1 | |
| SCHEMBL29588316 | 0.85 | AXL (0.56) | AXLPRKCIJAK2JAK3JAK1 | |
| SCHEMBL29588238 | 0.85 | AXL (0.56) | AXLPRKCIJAK2JAK3JAK1 | |
| SCHEMBL28735132 | 0.85 | AXL (0.56) | AXLPRKCIJAK2JAK3JAK1 | |
| SCHEMBL12875920 | 0.84 | AXL (0.51) | AXLPRKCIJAK2JAK3JAK1 | |
| SCHEMBL12876261 | 0.84 | AXL (0.54) | AXLPRKCIJAK2JAK3JAK1 | |
| SCHEMBL12876743 | 0.82 | JAK2 (0.53) | PRKCIJAK2JAK3JAK1TYK2 | |
| SCHEMBL30985188 | 0.81 | AXL (0.55) | AXLPRKCIJAK3JAK1NUDT1 | |
| SCHEMBL2115690 | 0.81 | AXL (0.55) | AXLPRKCIJAK3JAK1NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023129512-A1 | BICYCLIC INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE, COMPOSITIONS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023116779-A1 | DIALKYNE COMPOUND AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116779-A1 | DIALKYNE COMPOUND AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| EP-3919494-B1 | JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF | JIANGSU VCARE PHARMATECH CO LTD (CN) | 2023-05-24 | — | — | EP | disclosed |
| US-20220185816-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD (CN) | 2022-06-16 | — | — | US | disclosed |
| US-20220177467-A1 | Janus Kinase (JAK) Family Inhibitor, Preparation of Same, and Applications Thereof | JIANGSU VCARE PHARMATECH CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| CN-111518096-B | Janus kinase JAK family inhibitor and preparation and application thereof | 江苏威凯尔医药科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3939979-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2022-01-19 | — | — | EP | disclosed |
| EP-3919494-A1 | JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF | Jiangsu Vcare Pharmatech Co., Ltd (CN) | 2021-12-08 | — | — | EP | disclosed |
| CN-108570048-B | Substituted heteroaryl compounds, compositions and uses thereof | 广东东阳光药业有限公司 | 2021-06-08 | — | — | CN | disclosed |
| US-8163767-B2 | Heterocyclic Janus Kinase 3 inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| CN-101351466-B | Heterocyclic Janus kinase 3 inhibitors | ASTELLAS PHARMA INC | 2011-08-10 | — | — | CN | disclosed |
| CN-102127078-A | Heterocyclic janus kinase 3 inhibitors | ASTELLAS PHARMA INC | 2011-07-20 | — | — | CN | disclosed |
| US-20110039822-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2011-02-17 | — | — | US | disclosed |
| US-7879844-B2 | useful for treating or preventing diseases caused by undesirable cytokine signal transmission such as autoimmune diseases, inflammatory diseases, allergies, transplant rejection, multiple sclerosis, arthritis, psoriasis, asthma, dermatitis, Alzheimer's disease, atherosclerosis, cancer and leukemia | ASTELLAS PHARMA INC. (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2251341-A1 | Heterocyclic Janus kinase 3 inhibitors | Astellas Pharma Inc. (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20090270376-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-22 | — | — | US | disclosed |
| CN-101351466-A | Heterocyclic Janus kinase 3 inhibitors | ASTELLAS PHARMA INC (JP) | 2009-01-21 | — | — | CN | disclosed |
| CN-101223168-A | Heterocyclic JANUS kinase 3 inhibitors | ASTELLAS PHARMA INC (JP) | 2008-07-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177467-A1 | Janus Kinase (JAK) Family Inhibitor, Preparation of Same, and Applications Thereof | JAK1, JAK3, JAK2 | AXL 478/4885PRKCI 381/4885JAK2 3/4885 |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK2, JAK1 | AXL 313/4885PRKCI 179/4885JAK2 2/4885 |
| US-20110039822-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK1, JAK2 | AXL 973/4885PRKCI 340/4885JAK2 3/4885 |
| US-20220185816-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | JAK1, JAK2, JAK3 | AXL 469/4885PRKCI 219/4885JAK2 2/4885 |
| US-20090270376-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK1, IRAK3 | AXL 760/4885PRKCI 416/4885JAK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.